Elscint's second-quarter results sag
Elscint's second-quarter results sag It was a case of good newsand bad news this month for Elscint Ltd., which reported financialresults for the second quarter (end-June). On one hand, the Israelivendor reported that sales of its CT Twin family of
Elscint's second-quarter results sag It was a case of good newsand bad news this month for Elscint Ltd., which reported financialresults for the second quarter (end-June). On one hand, the Israelivendor reported that sales of its CT Twin family of scanners werestronger than expected. On the other, overall revenues for thequarter dropped 9% due to the ongoing slump in nuclear medicinesales in North America.
Revenues for the second quarter of 1994 totaled $54.7 million,down from the $60.3 million recorded in the same period last year.Net income was down sharply, to $2.7 million from $7.2 millionin last year's second quarter, a drop of 63%.
Depressed market conditions in North America have caused intensecompetition and aggressive pricing, which have impacted margins,according Shmuel Parag, president and CEO of Haifa-based Elscint.The nuclear medicine market is down 25% in the first two quartersof 1994, according to data from the National Electrical ManufacturersAssociation, Parag said.
The company saw a 10% increase in the order backlog for itsCT-Twin family, however. CT scanner sales, as well as cost-cuttingmeasures Elscint has already implemented, should improve the company'sresults beginning in the fourth quarter of this year.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
